Against the backdrop of aging, chronic diseases, and a growing population, the healthcare system is going through a vital transformation. Healthcare is simply becoming increasingly individual-centric.

Stratos Wealth Partners LTD. purchased a new stake in DexCom, Inc. (NASDAQ:DXCM – Free Report) in the fourth quarter, HoldingsChannel.com reports. The fund purchased 2,583 shares of the medical device ...

Dexcom stock stock recovered Friday after the diabetes devices maker missed fourth-quarter profit expectations.

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...

JAMA today published outcomes from a study evaluating the safety and efficacy of the Insulet Omnipod 5 in adults with type 2 ...

DexCom reported Q4 revenue of $1.11 billion, surpassing estimates. The company reaffirmed its 2025 outlook while analysts ...

Adults with insulin-treated type 2 diabetes had a significant HbA1c decline at 13 weeks with use of the Omnipod 5 automated ...

San Diego, California-based DexCom, Inc. (DXCM) is a medical device company that focuses on the design, development, and ...

Stifel Nicolaus analyst Mathew Blackman reiterated a Buy rating on Dexcom (DXCM – Research Report) today and set a price target of $100.00. The ...

Baird raised the firm’s price target on DexCom (DXCM) to $115 from $104 and keeps an Outperform rating on the shares. The firm said the second ...

Looking forward, DexCom's management has reiterated its fiscal year 2025 forecast, anticipating revenue growth of 14% with a ...

Dexcom (Nadsaq:DXCM) shares fell after hours today on fourth-quarter results that came in mixed compared to the consensus forecast.